Congenital Heart Center
Extraordinary Heart Care for Patients with Pediatric and Congenital Heart Disease (CHD) FROM
FETAL LIFE THROUGH ADULTHOOD
WHY CHOOSE US
EXTENSIVE EXPERIENCE
• As an international referral center, the Congenital Heart Center at University of Michigan Health C.S. Mott Children’s Hospital is one of the largest and most experienced programs worldwide
EXPERT TEAM, DEDICATED SERVICES
• Expert specialists across every facet of heart care, spanning the most common disorders to groundbreaking therapies for complex cases
• Dedicated inpatient and outpatient units with specialized cardiac teams providing 24/7 care
RELENTLESS FOCUS ON OPTIMIZING QUALITY AND OUTCOMES
• Excellent outcomes for our highly complex patient population
• We lead multiple ongoing projects geared toward improving quality and safety, and sharing best practices to enhance care for children with heart disease around the country
COMPREHENSIVE LIFELONG CARE
• Seamless care from fetal life through adulthood, focused on enhancing long-term outcomes and quality of life
• On-site Von Voigtlander Women’s Hospital birthing center and collaboration with Frankel Cardiovascular Center’s top-ranked adult cardiac surgery program
• Longitudinal Follow-Up Program, Interstage Home Monitoring, Single Ventricle Multidisciplinary FollowUp Clinic and Neurodevelopmental Program
• New Cardiac Home Advanced Monitoring Program and Psychosocial Support (CHAMPPS) Program
COORDINATED CARE, CLOSE TO HOME
• 13 clinic locations in Michigan and northern Ohio, and collaborating partners across the region bring our expert clinicians close to you
• Remote echocardiography and telemedicine capabilities
• Comprehensive transport services
INNOVATIVE TREATMENTS AND CUTTING-EDGE RESEARCH
• Leaders in research and innovation, providing patients with access to the latest treatments, devices and clinical trials
• Pediatric Heart Network core site
• Leaders in multicenter QI and clinical outcomes registries
FAMILY SUPPORT AND RESOURCES
• Patient and Family Centered Care program, on-site Ronald McDonald House, support for travel and lodging coordination, hospital school services, spiritual care, psychological support and many other resources
2025 HIGHLIGHTS AT A GLANCE
NEW CO-DIRECTOR FOR CONGENITAL HEART CENTER NAMED
Kurt Schumacher, M.D., assumed the role of Division Director of Pediatric Cardiology at C.S. Mott Children’s Hospital and Co-Director of the Congenital Heart Center in December. Prior to his new appointment, Dr. Schumacher was associate director of M-CHORD (Michigan Congenital Heart Outcomes Research and Discovery clinical research unit), associate director of the pediatric cardiology fellowship, director of the Pediatric Cardiac Critical Care Consortium (PC4) analytic center, and medical director of the Pediatric Heart Transplant Program at C.S. Mott Children’s Hospital. John Charpie, M.D., served as Division Director of Pediatric Cardiology at C.S. Mott Children’s Hospital and Co-Director of the Congenital Heart Center for 16 years and continues to serve as a faculty member in pediatric cardiology at C.S. Mott Children’s Hospital.
EXPANDING EXCELLENCE IN PSYCHOSOCIAL CARE: GROWTH AND INNOVATION IN THE M-COPE PROGRAM
The M-COPE Psychosocial and Educational Program, directed by Melissa Cousino, Ph.D., continues to be a globally recognized model of embedded psychosocial clinical care and research within pediatric cardiac care. The M-COPE team has grown to 20 heart-center dedicated psychosocial clinicians over the past year with noteworthy additions including, Caitlin McCarthy, M.D., a newly integrated perinatal psychiatrist specializing in parental mental health care, and cardiac psychologist, Kelly Rea, Ph.D., a transition — and ACHD-focused mental health expert. Additionally, M-COPE partnered with hospital music therapy to bring on a heart-center dedicated music therapist — enabling the center to offer inpatient music therapy groups specifically for patients on inpatient cardiac units and post-surgical
rehabilitation using voice therapy. Patient- and programfocused research remains core to the M-COPE program. The center is proud to be a leader of the Pediatric Heart Network funded multi-site WE BEAT CHD Study investigating the effectiveness of the WE BEAT virtual, group resiliency-building program in adolescent CHD — a program that was developed and first piloted in the Congenital Heart Center.
CLINICAL TRIAL LAUNCHED TO STUDY 3D PRINTED DEVICE FOR RARE RESPIRATORY DISEASE
Michigan Medicine and Materialise launched a new clinical trial that will allow researchers to study 3D-printed bioresorbable devices aimed at treating children with the rare and life-threatening airway condition tracheobronchomalacia.
INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION APPOINTS M-COPE DIRECTOR AS PROGRAM CHAIR
Melissa Cousino, Ph.D., director of the M-COPE Psychosocial and Educational Program at C.S. Mott Children’s Hospital, was announced as the Scientific Program Chair for the International Society for Heart & Lung Transplantation (ISHLT)’s 47th Annual Meeting & Scientific Sessions, taking place in Syndey, Australia in April 2027. Dr. Cousino will be the first non-physician ISHLT member to hold this position.
AI-POWERED FLUID MANAGEMENT SYSTEM PROVES FEASIBILITY IN ANIMAL STUDIES
Fluid management is a cornerstone of postoperative management following congenital heart surgery. Researchers at the Congenital Heart Center, led by Daniel Ehrmann, M.D., pediatric cardiologist, have developed an AI-powered software to help semiautomate fluid management with a diuretic infusion. The project, called OTTO, is a collaboration with the Department of Computational Medicine and Bioinformatics, and received two additional grants in 2025 to fund further development. The team recently demonstrated that the system works as intended in the animal laboratory and is beginning planning for first-inhuman studies.
THE CONGENITAL HEART CENTER EXPANDS TRAINING AND EP PROGRAMS IN RWANDA
The C.S. Mott Children’s Hospital Congenital Heart Center is having a global impact. Beginning with a prestigious Fulbright U. S. Scholar Grant and continuing over five years, David Bradley, M.D., pediatric cardiologist, has made extended visits to Rwanda. He assisted their Ministry of Health and Universities to establish the first cardiac training programs in the country. In addition, with support from his colleagues, he has established a global health rotation in Rwanda for pediatric cardiology fellows from Michigan. Dr. Bradley has also facilitated visits for Rwandan learners and specialists to observe Michigan Medicine facilities. Most recently he helped launch Rwanda’s first electrophysiology program.
CONGENITAL HEART CENTER TEAM UTILIZES TOTAL ARTIFICAL HEART FOR MICHIGAN 10-YEAR-OLD WITH MYOCARDITIS
A 10-year-old patient at C.S. Mott Children’s Hospital became the first child to receive total artificial heart in Michigan and is believed to be one of the youngest and smallest patients in the world to have undergone a total artificial heart implantation after a sudden cardiac arrest. Tim Lancaster, M.D., pediatric heart surgeon, led the surgery with support from David Peng, M.D., pediatric cardiologist and the director of pediatric heart failure and mechanical circulatory support.
EXPANDING ACCESS TO EXERCISE MEDICINE
HEART Club, our telemedicine-based exercise program, delivers individualized training and coaching directly to patients’ homes — removing traditional barriers to cardiac rehabilitation while building fitness, confidence, and lifelong activity habits. Our research showed HEART Club improved exercise capacity and reduced frailty with no serious adverse events, prompting HEART Club’s transition from research study to clinical program. To advance the field beyond our institution, we founded the Pediatric Exercise Data Analytics and Learning Network (PEDAL), a multi-center consortium working to standardize exercise testing protocols, enable collaborative research, and share resources that help other programs build exercise medicine capacity for their patients with congenital heart disease.
PROGRAMS AND CLINICS AT A GLANCE
The Congenital Heart Center at University of Michigan Health is located in the state-of-the-art C.S. Mott Children’s Hospital, a 346-bed, free-standing facility.
Adult Congenital Heart Program
ACHA-accredited program staffed by ACHD boardcertified cardiologists, more than 4,700 visits in 2025
Cardiac Anesthesia Service
10 pediatric cardiac anesthesiologists providing comprehensive anesthesia services
Cardiac Catheterization
Staffed by four pediatric interventional cardiologists with advanced training, performing more than 800 cases in 2025 spanning the full spectrum of congenital heart disease
Cardiac Genetics Clinic
Multidisciplinary team (cardiology, genetics and genetic counseling services) providing coordinated screening, diagnosis, management and counseling for patients with heritable cardiac conditions
Cardiac MRI
Staffed by four pediatric cardiologists with advanced magnetic resonance imaging (MRI) training, over 700 pediatric and adult congenital heart disease studies performed in 2025
Cardiac Nursing and Advanced Practice
Providers (APPs)
Specialized inpatient and outpatient teams with prestigious nursing Magnet designation and a team of 39 APPs (nurse practitioners and physician assistants) in various subspecialities caring for children and adults with congenital heart disease
Cardio-Oncology Long Term Follow-Up Clinic
Cardiology and oncology provide specialized care for children with a high risk of developing cardiovascular health complications as a result of cancer treatment
Cardiology Clinics
General and specialty clinics for patients with all forms of congenital and pediatric heart disease at 13 locations across Michigan and northern Ohio
Complex Biventricular Repair Program
Comprehensive surgical planning and innovative procedures to achieve two-ventricle circulation in children with complex anatomy
Congenital Cardiac Surgery
High-volume international referral center, four congenital cardiac surgeons, two dedicated ORs
Echocardiography
Staffed by 14 Mott hospital-based pediatric cardiologists, nine community-based pediatric cardiologists and 14 sonographers with expertise in pediatric and congenital 2D, 3D, transesophageal, and fetal imaging, performing more than 19,000 studies in 2025 across Mott and outreach locations
Electrophysiology & Heart Rhythm Program
Providing a full spectrum of pediatric arrhythmia care including consultation, catheter ablation, cardiac device care, and treatment of genetic arrhythmia syndromes
Exercise Physiology & Vascular Lab
Offers comprehensive cardiopulmonary exercise testing and vascular assessments for children and adults with congenital heart disease. Our therapeutic programs combine exercise prescription with coaching and education—including telemedicine-based home training—to help individuals with congenital heart disease build fitness, confidence, and the skills to stay active for life.
Heart Failure & Transplant
Staffed by four pediatric heart failure/transplant specialists with advanced training and three specialized advanced practitioners. We had more than 640 outpatient visits in 2025 and 8 heart transplants, as well as 6 children supported with ventricular assist devices (VAD). Our team has internationally recognized expertise in advanced heart failure management,
cardiomyopathy and VAD especially among patients with single ventricle circulation and complex congenital heart disease.
Hybrid Intervention
Experienced team of surgeons and interventional cardiologists performing hybrid procedures for high-risk single ventricle patients, marginal biventricular repair candidates, complex pulmonary artery interventions, muscular ventricular septal defects and bridge to transplantation
Interstage Home Monitoring
Home monitoring services, care coordination, and education for single ventricle patients and other types of staged surgery
Muscular Dystrophy Clinic
Multidisciplinary clinic (cardiology, neurology, and physical medicine and rehabilitation) serving patients with a wide range of neuromuscular disorders
Neurodevelopmental Program
Multidisciplinary team (cardiology, psychology, neurology, nursing and social work) providing unique inpatient consultation, outpatient evaluation of neurodevelopmental and behavioral concerns, and referral for appropriate treatments
Pediatric Acute Cardiac Care Unit
32-bed unit, multidisciplinary patient-centered pediatric heart care
Pediatric Cardiothoracic Intensive Care Unit
Dedicated cardiac intensive care unit consisting of 21 beds staffed 24/7 by in-house cardiac ICU doctors. We care for >500 patients per year who need specialized care for their cardiac conditions, including patients before and after cardiac surgeries as well as those with acquired heart conditions.
Prenatal Program & Fetal Intervention
With over 1,000 fetal echocardiograms performed at our main hospital and more than 900 fetal echos across eight outreach locations in 2025, the Prenatal Heart Program offers a complete range of fetal heart services, extensive counseling, and the full spectrum of fetal cardiac interventions. Care is integrated seamlessly with Von Voigtlander Women’s Hospital, located in the same building as Mott.
Pulmonary Hypertension
Inpatient and outpatient services providing comprehensive evaluation, treatment and follow-up for pulmonary hypertension
Preventive Cardiology Clinic
Specialized care for children with abnormal lipid levels or hypertension to reduce cardiovascular risk
Pulmonary Vein Anomalies Program
Multidisciplinary team (surgeons, interventional cardiologists and a nurse practitioner) developed for the diagnosis and management of pulmonary vein
stenosis in patients with repaired pulmonary vein anomalies associated with complex CHD and those with prematurity and primary pulmonary vein stenosis
Psychosocial & Educational Program (M-COPE)
Renowned psychosocial care program for patients and families across outpatient and inpatient cardiac care. Our team of heart-center dedicated psychologists, perinatal psychiatrist, social workers, child life specialists, education liaisons, and peer mentors provide emotional support, mental health care, and educational services, as well as lead various related research studies.
Single Ventricle Follow-Up Clinic
Multidisciplinary team (cardiology, gastroenterology, nephrology, neurology, psychology and more) providing comprehensive, coordinated longitudinal care and education for single ventricle patients in coordination with their primary cardiologist
Transition Program
Multidisciplinary team of nurse practitioners, psychologists, social workers, cardiologists and exercise specialists, addressing medical, educational and psychological needs specific to each pediatric patient transitioning to adult care. Nearly 200 transition visits annually offered to patients across the statewide Congenital Heart Center network of providers.
VOLUMES AND OUTCOMES
CARDIAC SURGERY
Our congenital cardiac surgery program is considered one of the highest-volume programs in the nation.*
2025 TOTAL CARDIAC SURGERY VOLUME
*250 cases/year is the benchmark used by the Society of Thoracic Surgeons (STS) to define high-volume centers
We are among the most experienced programs in the nation with high complexity (STAT 5) cases. FY 2021–2025 STAT 5 CASES
Excellent outcomes for our highly complex patient population compared to national benchmarks.
MORTALITY BY STAT CATEGORY
Our postoperative length of stay (LOS) is substantially shorter compared to national benchmarks.
POSTOPERATIVE LOS
CLINIC VISITS
12,833 ECHOCARDIOGRAMS
20,550 CATHETERIZATIONS
817
Major complication rate 0.24%
QUALITY IMPROVEMENT
Our unique multidisciplinary quality team spans the Congenital Heart Center and leads multiple ongoing initiatives aiming to optimize quality of care and patient outcomes.
Reducing Central Line Associated Blood Stream Infections in Our Congenital Heart Center
Central Line Associated Blood Stream Infections (CLABSIs) are serious blood stream infections which can occur when a central line is present. These central lines are crucial to providing critical medications to patients as well as for obtaining lab testing without the trauma of multiple needle pokes. Given this we have worked as a center to reduce and keep our CLABSI rate low so that we can continue to provide safe patient centered care. We assembled a multidisciplinary group in our Congenital Heart Center, including front-line nursing champions, to assess our current central line
EPS/ABLATION PROCEDURES
153 CARDIAC DEVICE PROCEDURES
41 TRANSPLANTS
8 93.75% 1-year survival over the most recent 30-month evaluation period
CARDIAC ICU
Our expert care helps patients recover quickly after congenital heart surgery, with short stays in the cardiac intensive care unit (CICU).
Postoperative CICU Length of Stay
maintenance practices and define best practices moving forwards. This group created a multi-intervention approach to prevent CLABSIs on our units which included reducing needs to access the lines, having more robust conversations about line necessity, and improving the hygiene of patient room environments. This work resulted in a 67% reduction in CLABSIs across the Congenital Heart Center. This work highlights the ability to reduce CLABSIs for our patients while still maintaining central access that provides many patientcentered benefits. 2025
n U-M n OTHER SITES
SOURCE: Pediatric Cardiac Critical Care Consortium (PC4) TIME FRAME: 2023–2025 data vs. other high-volume sites
RESEARCH AND INNOVATION
We support groundbreaking research and innovation geared toward driving improvements in care and outcomes and developing new therapies for the next generation.
Michigan Congenital Heart Outcomes Research and Discovery (M-CHORD) Program
M-CHORD is our unique research core within the Congenital Heart Center supported by dedicated faculty and staff. Our comprehensive expertise spans the spectrum of clinical and translational investigation and accelerates novel and collaborative science.
Cardiac Networks United (CNU) Data Core
We lead Data Core activities for CNU, which integrates ten large networks spanning more than two thirds of the nation’s congenital heart programs. The Data Core houses one of the largest collections of CHD data worldwide and accelerates collaborative research and quality improvement activities.
Pediatric Heart Network (PHN) Core Site
We are one of nine centers across the country selected to participate in the PHN, funded by the National Institutes of Health. Mott has continuously served as a PHN site since 2011, and we were recently selected to continue participation for another seven years, through 2030. Through this network our patients have access to clinical trials of cutting-edge therapies and interventions. A list of active studies can be found at: www.pediatricheartnetwork.org/studies.
U-M Investigators collaborated with the PHN to lead a variety of efforts in 2025. Examples include:
• A Multicenter Trial to Foster Resilience in Teens with CHD: First developed and piloted at U-M, the WE BEAT Wellbeing Education Program is a telemedicine-delivered, psychologist-led, group-based program aimed at fostering resilience and wellbeing in young people with CHD. A multicenter pragmatic clinical trial of the program, WE BEAT CHD, will be launched through the PHN and
14 participating sites in early 2026 — representing the first-ever adolescent mental health focused multisite trial in CHD supported by PHN and NHLBI. In addition to patient-reported psychosocial outcomes, the trial will capture medical data and biomarkers of stress, inflammation, and cardiac functioning.
• COMPASS Trial and Registry: Comparison of Methods of Pulmonary Blood Flow Augmentation in Neonates: Shunt Versus Stent (COMPASS) — the first randomized trial to compare a catheter-based intervention vs. surgery in the CHD population. U-M investigators are collaborating with the PHN and two national CNU registries to lead the COMPASS trial and companion registry, which is studying infants with ductal-dependent pulmonary blood flow. The trial started in 2022 with U-M as the first site to enroll patients in the study.
• Longitudinal Follow-Up for Patient’s Enrolled in the Original Single Ventricle Reconstruction Trial (SVR III): This PHN study is co-led at U-M and is the largest prospective study to date of children with hypoplastic left heart syndrome (HLHS). Because of the study and the significant commitment of all the study participants, families have learned and continue to learn a great deal about the optimal surgical and medical approaches to treat individuals with HLHS.
• FUEL-2: Congenital Heart Center investigators are a participating site in this large, multicenter trial to study the efficacy of a medication to improve exercise performance in patients with surgically palliated single ventricle congenital heart disease.
• Biorepository: U-M leads biorepository efforts for the PHN, supporting investigations in the precision medicine realm to understand unique traits influencing CHD outcomes.
• Genetic Determinants of Ventricular Function and Exercise Performance After the Fontan Procedure: In collaboration with the PHN, U-M investigators will lead a study examining the genetic determinants of exercise performance and ventricular function in patients who have had a Fontan procedure. The study promises to provide important insights into the signaling pathways that determine whether a patient will be healthy or have a more difficult course after a Fontan procedure. Understanding these differences may allow the development of novel treatment strategies to improve the health and enhance the quality of life in patients who have had a Fontan procedure.
ADDITIONAL 2025 RESEARCH HIGHLIGHTS:
T-NOX Trial Update
U-M investigators completed enrollment in the T-NOX trial in 2023, which compared strategies for oxygen delivery (normal versus high levels) in infants undergoing congenital heart surgery. The data has been published in a manuscript and there is a growing interest to bring this to a multicenter study.
Fontan Long-Term Outcomes
U-M cares for one of the largest populations of Fontan patients worldwide, and our investigators lead multiple projects focused on improving long-term Fontan outcomes. Studies include:
• Fontan Circulatory Failure Study: U-M is the lead site for the largest study to date examining the role of Fontan-associated complications, frailty and resilience on heart failure outcomes. The retrospective portion of the study enrolled more than 400 patients with Fontan physiology listed for heart transplant and found Fontan-specific factors that were associated with death before and after transplant. The study was presented at the American Heart Association 2023 and 2024 Scientific Sessions and received the award for most outstanding research in pediatric cardiology. The prospective arm of the study is ongoing and has enrolled nearly 100 patients with Fontan physiology and heart failure to assess how frailty and resilience affects their outcomes.
• Fontan Mental Health Study: We are the lead site for this PHN-funded study looking at the associations between social determinants of health and mental health in patients with Fontan circulation. This study uses self-reported and parent-reported measures to assess psychological functioning and adverse social determinants of health in 130 patients. We are finishing enrollment across 5 different congenital heart centers, and anticipate finalizing the study in 2026.
• Fontan Placenta Study: As an increasing number of patients with the Fontan procedure are aging into adult care, more are interested in pursuing pregnancy. This study is looking at the outcomes of pregnancy in women with Fontan physiology, specifically looking at the placenta as a mediator of both maternal and fetal outcomes. With PHN support and funding, we are now expanding this study to include three other ACHD centers across the US to better understand pregnancy outcomes and better inform cardiologists and obstetricians on pregnancy care in this unique but rapidly growing population.
OTHER STUDIES:
New Treatments for Heart Transplant Recipients: U-M participated in the first multi-center randomized trial conducted in pediatric heart transplantation which was published in JAMA (“Everolimus and Low-
michmed.org/2025CHCpubs
Dose Tacrolimus After Heart Transplant in Children.”)
This project, which involved 25 sites across the United States, demonstrated the safety/tolerability of this immunosuppression regimen and its possible association with improved kidney function and less infection.
PCGC: We actively participate in the Pediatric Cardiovascular Genomics Consortium, a multi-site team examining the genetic determinants of congenital heart disease and their associated clinical outcomes. We have been involved in a number of collaborative efforts to identify new CHD disease genes, and genetic determinants of Neurodevelopmental outcomes and ventricular function.
GenoMISC: This NIH-funded study, led by a U-M investigator (Russell), will examine the genetic determinants of the severity and cardiac manifestations of MIS-C, a post-COVID hyperinflammatory state associated with significant morbidity. The study cohort will be 400 subjects enrolled in the PHN’s MUSIC study, which described the clinical features of children affected with Multisystem Inflammatory Syndrome after COVID in children (MIS-C).
Clinical trials in pediatric patients with hypertrophic cardiomyopathy: Myosin inhibitors have emerged as a novel and potentially exciting treatment approach for patients with Hypertrophic Cardiomyopathy. After
very promising results in adults, clinical trials were developed for the pediatric patient population. The SCOUT-HCM and CEDAR Trials are the first trials of myosin inhibitors, mavacamten and aficamten respectively, in pediatric patients with HCM in the US and the U-M (site PI: Russell) enrolled the first patient for the SCOUT-HCM Trial, which has completed patient enrollment, and has now enrolled 2 patients in the CEDAR trial. Dr. Russell was invited to serve as a consultant for the CEDAR trial and has helped to develop strategies to aid study enrollment.
AI-powered fluid management system proves feasibility in animal studies: Fluid management is a cornerstone of postoperative management following congenital heart surgery. Researchers at the Congenital Heart Center, led by Daniel Ehrmann, MD, MS, have developed an AI powered software to help semi-automate fluid management with a diuretic infusion. The project, called OTTO, is a collaboration with the Department of Computational Medicine and Bioinformatics, and has received two additional grants in 2025 to fund further development. The team recently demonstrated that the system works as intended in the animal laboratory and is beginning planning for first-inhuman studies.
Airway Splint Clinical Trial: Investigators at U-M and industry partner Materialise launched a new clinical trial that will allow researchers to study 3D-printed bioresorbable devices aimed at treating children with the rare and life-threatening airway condition tracheobronchomalacia (TBM). TBM causes the airway to collapse, making breathing difficult and, in severe cases, can be fatal. Currently, infants with this condition often rely on ventilators to survive. The University of Michigan-developed 3D-printed bioresorbable airway splint device is implanted surgically around the outside of the of the trachea or mainstem bronchi to hold the airway open and prevent collapse. Because it is bioresorbable, the device does not need to be removed as a child grows, since it will be resorbed into the body. Research teams plan to enroll 35 infants in the eightyear study from Mott, as well as three other children’s hospitals across the country, with devices produced by Materialise.
Congenital Heart Center
1540 East Hospital Drive
Ann Arbor, MI 48109-4204
Patients and Families
1-734-764-5176
EXPERT CARE, CLOSE TO HOME AND ACROSS THE GLOBE
Nearly
uofmhealth.org/ped-heart
COORDINATED SERVICES FOR FAMILIES TRAVELING FOR CARE
• Experience providing seamless care for children around the country and across the globe with ~20% of our congenital heart surgery patients traveling to Mott for expert care from out of state
• Remote echocardiography and telemedicine capabilities
• Comprehensive transport services when transfer is needed
PATIENT AND FAMILY SUPPORT SERVICES
• Patient and Family Centered Care and peer-mentoring program
• On-site Ronald McDonald House
• Travel and lodging coordination and support
• Hospital school and educational services
• Spiritual care
• Child life
• Music, art, technology and pet therapy services
• Social